Review anchor
Tyrosine-protein kinase Blk
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
Evidence Snapshot
Tyrosine-protein kinase Blk
CHEMBL3343
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Blk as ChEMBL target CHEMBL3343, mapped to UniProt P16277. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3343
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P16277
Tyrosine-protein kinase Blk
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Tyrosine-protein kinase Blk matters
Tyrosine-protein kinase Blk is reviewed as Tyrosine-protein kinase Blk (UniProt P16277); the current evidence base includes 2 approved drugs, 38 compounds, and 20 assays, with lead potency reaching pChEMBL 8.1.
Protein context
Tyrosine-protein kinase Blk
Tyrosine-protein kinase Blk Sequence length is 499 aa.
Review this target as Tyrosine-protein kinase Blk, mapped to UniProt P16277. Sequence length is 499 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P16277
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 38 compounds, and 20 assays for this target. The dominant activity type is IC50. CHEMBL288441 is the current potency anchor at pChEMBL 8.1.
Use CHEMBL288441 as the tractability anchor when discussing potency (pChEMBL 8.1).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 8.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Tyrosine-protein kinase Blk matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P16277, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
38
Total Compounds
20
Total Assays
2
Approved Drugs
IC50: 21.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL288441
|
8.1 | IC50 | Approved |
|
|
No preferred name
CHEMBL2010872
|
8.1 | IC50 | Clinical |
|
|
No preferred name
CHEMBL5416410
|
8.1 | IC50 | Approved |
|
|
No preferred name
CHEMBL388978
|
6.4 | IC50 | — |
Approved Drugs
Source Header